SHANGHAI, China, June 15, 2026
CARsgen Therapeutics Holdings Limited has unveiled encouraging clinical data for its investigational allogeneic CAR T-cell therapies CT0596 and CT1190B at the European Hematology Association (EHA) 2026 Congress, highlighting the growing potential of next-generation cell therapies for difficult-to-treat blood cancers. The presentations showcased positive efficacy and safety outcomes across patients with relapsed/refractory multiple myeloma (R/R MM), primary plasma cell leukemia (PCL), and B-cell non-Hodgkin lymphoma (B-NHL). Developed using CARsgen’s proprietary THANK-u Plus® platform, both candidates are designed as allogeneic “off-the-shelf” CAR-T therapies, potentially offering broader accessibility and faster treatment availability compared with traditional autologous CAR-T products. The latest findings reinforce the company’s commitment to advancing innovative immunotherapies capable of addressing significant unmet medical needs in hematologic malignancies and autoimmune diseases.
CT0596 Demonstrates Deep Responses in Multiple Myeloma and Plasma Cell Leukemia
The EHA presentation highlighted data from eight heavily pretreated patients receiving CT0596, an allogeneic BCMA-targeted CAR-T therapy. The study included six patients with relapsed/refractory multiple myeloma and two patients with relapsed/refractory primary plasma cell leukemia. Despite advanced disease characteristics and high-risk cytogenetics among most participants, the therapy demonstrated encouraging efficacy and a manageable safety profile. As of May 2026, six patients maintained ongoing responses following treatment. Among evaluable patients, five achieved stringent complete responses (sCR) while one achieved a very good partial response (VGPR). Importantly, both plasma cell leukemia patients achieved stringent complete responses.
All patients who responded to therapy achieved minimal residual disease (MRD) negativity at a sensitivity level of 10⁻⁶, a key marker associated with deep and durable disease control. Safety findings were also notable, with no reports of grade 3 or higher cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity syndrome (ICANS), no graft-versus-host disease (GVHD), and no treatment-related deaths. Pharmacokinetic analyses further demonstrated strong and sustained CAR-T cell expansion, supporting the biological activity of the therapy.
CT1190B Shows High Response Rates in B-Cell Non-Hodgkin Lymphoma
Advertisement
CARsgen also presented updated results for CT1190B, an allogeneic CAR-T therapy targeting both CD19 and CD20, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Thirteen heavily pretreated patients received CT1190B across multiple dose levels, including patients with large B-cell lymphoma and follicular lymphoma. Among twelve evaluable patients, the therapy achieved an impressive objective response rate (ORR) of 91.7%, with a complete response rate of 66.7%. Notably, all three patients with follicular lymphoma achieved complete responses, while strong responses were also observed among patients who had previously received CAR-T therapies or bispecific antibody treatments. The majority of severe adverse events were manageable hematologic toxicities, and no treatment-related deaths or study discontinuations occurred.
Cytokine release syndrome was generally low grade and resolved successfully in affected patients. CAR-T expansion data demonstrated robust biological activity, particularly at higher dose levels, with pharmacokinetic measurements exceeding those reported for several currently approved autologous CAR-T products. These findings support the potential of CT1190B as a powerful treatment option for patients with relapsed or refractory B-cell malignancies.
Advancing the Future of Off-the-Shelf Cell Therapy
The latest EHA 2026 data strengthen CARsgen’s position within the rapidly evolving cell and gene therapy sector, where allogeneic CAR-T platforms are increasingly viewed as a promising solution to overcome manufacturing complexity, treatment delays, and scalability challenges associated with autologous therapies. Both CT0596 and CT1190B demonstrated favorable safety profiles and encouraging clinical activity across multiple hematologic cancers, providing further validation for the company’s proprietary THANK-u Plus® platform.
CARsgen plans to initiate Phase Ib clinical trials for CT0596 in relapsed/refractory multiple myeloma and primary plasma cell leukemia, as well as CT1190B in relapsed/refractory B-cell non-Hodgkin lymphoma during 2026. As researchers continue to explore the broader potential of allogeneic CAR-T technologies in cancer and autoimmune diseases, these findings highlight the growing role of innovative cell therapies in transforming treatment options for patients with limited therapeutic alternatives worldwide.
Source: CARsgen Therapeutics press release
